Bioventus Opens 2024 With Strong Growth Across Biologics Businesses

Bioventus reported 1Q24 orthopedic sales of $112.5 million, up 14.6% compared to the first quarter of 2023.

The company drove strong results for its non-surgical hyaluronic acid (HA) pain treatments and surgical bone graft substitutes (BGS), with both growing in the double digits.

With reimbursement headwinds now behind Bioventus' HA...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us